In NSCLC patients with high PD-L1 expression, the PD-L1 inhibitors is the first-line choice even for those with previously untreated metastasis (Taggart et al., 2018; Steindl et al., 2021). This evidence concerns the gene CD274 and non-small cell lung carcinoma.